REG - GENinCode PLC - Publication of Landmark Study in JACC: Advances

GenincodeAnnouncement

27/10/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251027:nRSa8411Ea&default-theme=true

RNS Number : 8411E  GENinCode PLC  27 October 2025

27 October 2025

GENinCode Plc

("GENinCode" or the "Company")

Publication of Landmark Study in JACC: Advances

Validation of CARDIO inCode-Score® for improved coronary heart disease risk
prediction

 

GENinCode Plc (AIM: GENI), the predictive genetics company focused on the
prevention of cardiovascular disease ("CVD") and risk assessment of ovarian
cancer, announces the publication of a major clinical study in JACC: Advances
evaluating the Company's CARDIO inCode-Score® Polygenic Risk Score ("PRS")
for coronary heart disease ("CHD"). JACC: Advances, a medical journal which is
part of the Journal of the American College of Cardiology (JACC), specifically
focuses on the latest research in cardiovascular medicine including new
treatments, technologies and scientific discoveries in Cardiology leading to
better clinical practices in the medical field.

 

The peer-reviewed study(1.), titled "Joint Consideration of LDL-C and
Polygenic Risk for Coronary Heart Disease Risk Assessment", was conducted by
researchers at Kaiser Permanente's Department of Research and Department of
Cardiology in San Francisco, California, USA.

 

Study Overview

The Kaiser Permanente study followed over 47,000 individuals of diverse
ancestry for 14 years, analysing the relationship between low-density
lipoprotein cholesterol (LDL-C) and polygenic risk for coronary heart disease.
Participants were assessed for the incidence of CHD events including
myocardial infarction (heart attack).

 

The CARDIO inCode-Score® PRS was used to quantify each participant's
inherited risk of CHD based on genetic variation across the genome. The study
examined whether the effect of LDL-cholesterol on CHD risk was modified by an
individual's underlying genetic risk.

 

Key Findings

The results demonstrated that genetic risk significantly influences the
relationship between LDL-cholesterol and coronary heart disease, with the
combination of elevated LDL-C and high PRS conferring substantially greater
risk.

 

·      Individuals with high polygenic risk experienced a 75% increase
in CHD risk at LDL-C levels as low as 100 mg/dL (2.6 mmol/L) (Hazard Ratio:
1.75).

·      At LDL-C levels of 130-160 mg/dL (3.4 - 4.1 mmol/L), risk
increased more than twofold (HR: 2.1).

·      The combination of a high PRS and LDL-C of 190 mg/dL (4.9 mmol/L)
or higher was associated with a greater than 3.5-fold increase in CHD risk,
comparable to the risk observed in patients with heterozygous familial
hypercholesterolemia (FH), a well-established genetic condition conferring
very high cardiovascular risk.

 

These findings confirm that polygenic risk acts as a powerful modifier of
LDL-cholesterol-related CHD risk, supporting its use in clinical
decision-making and preventive care.

 

Clinical and Preventive Implications

This study underscores the critical role that integrating genetic data with
clinical assessments can play in revolutionising cardiovascular risk
stratification and prevention and guide earlier intervention in at-risk
populations.

Individuals with high genetic risk may benefit from more proactive lipid
management and lifestyle or therapeutic intervention, even at LDL-C levels
traditionally considered low or moderate.

 

By integrating polygenic risk assessment into existing clinical pathways,
healthcare providers can more accurately identify individuals at heightened
lifetime risk of CHD and personalise prevention strategies. This can also
reduce the incidence of severe cardiovascular events, such as heart attacks
and strokes, and potentially mitigate the economic costs associated with
long-term heart disease care. This approach can be seen as a significant step
toward improving public health outcomes, particularly in addressing the global
burden of cardiovascular disease.

 

Dr. Richard Kovacs, Q.E. and Sally Russell Professor of Cardiology at the
Indiana University School of Medicine and Chief Medical Officer of the
American College of Cardiology and Past President of the American College of
Cardiology said: "These results provide further compelling clinical evidence
for the inclusion of polygenic risk scores (PRS) in conjunction with clinical
risk for improved risk assessment of CHD. The polygenic risk score is
especially important in relation to patients clinically classified at
borderline/intermediate risk and younger patients with a family history of
CHD. The recent scientific statements and acknowledgment of the value of PRS
by the American College of Cardiology and American Heart Association is also
welcome."

 

1. -  https://share.google/nQwFO73QgGTiRqK45
(https://urldefense.com/v3/__https:/linkprotect.cudasvc.com/url?a=https*3a*2f*2fshare.google*2fnQwFO73QgGTiRqK45&c=E,1,EEx91_2GmHsGoEUp0EQ-V27gIOE3J6byRyu3YPRqCVKSeN7K8QY-3kbawVh6w6yMNj2xqmJ9wErgqq0TTVRPpfwNelgXRv2ZVNt9ubgT76Lvv0smOEsP9_mw&typo=1__;JSUlJQ!!BZ50a36bapWJ!qZI0pZF8kQEd9cyUkVpHg1dSTwxhFlSMOMA29wSE_4dNRnMfIq-ZmkhGY5LuFIGXzFlSz1V5TGiV_jME$)

 

Notes to Editors

·      Hazard Ratio (HR) refers to the measure of relative risk over
time. For example, an HR of 2.0 indicates that an event (such as CHD) is twice
as likely to occur in one group compared to another.

·      LDL-cholesterol (LDL-C) is commonly referred to as "bad"
cholesterol and is a well-established modifiable risk factor for coronary
heart disease.

·      The Journal of the American College of Cardiology (JACC):
Advances is a leading peer-reviewed journal publishing high-quality
cardiovascular research.

 

For more information visit www.genincode.com (http://www.genincode.com)

 

Enquiries:

 GENinCode Plc                               www.genincode.com
                 (http://www.genincode.com) or via Walbrook PR
 Matthew Walls, CEO

 Cavendish Capital Markets Limited                                  Tel: +44 (0)20 7397 8900
 Giles Balleny (Corporate Finance)
 Nigel Birks (Life Sciences Specialist Sales)
 Harriet Ward (Corporate Broking)
 Dale Bellis / Michael Johnson (Sales)

 Walbrook PR Limited
 Anna Dunphy / Marcus Ulker       Tel: 020 7933 8780 or genincode@walbrookpr.com
                                  (mailto:genincode@walbrookpr.com)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCMFBMTMTMTTMA



            Copyright 2019 Regulatory News Service, all rights reserved